Patents Examined by Benjamin P. Blumel
  • Patent number: 10801055
    Abstract: Methods, devices, systems, and kits for use in detecting and measuring infectious diseases are provided. In particular embodiments, methods, devices, systems, and kits for detecting and measuring Ebola virus, including Ebola Zaire strain virus, are provided. Devices and systems may be used within regions suffering from Ebola or other infections, providing local, rapid, and effective diagnosis of infectious diseases such as Ebola, improving treatment and reducing or preventing spread of such infectious diseases.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: October 13, 2020
    Assignee: Labrador Diagnotstics LLC
    Inventors: Daniel Young, Elizabeth A. Holmes
  • Patent number: 10793834
    Abstract: Presented herein are live-attenuated viruses and methods of generating thereof from a parental virus through a plurality of nucleotide substitutions in the viral genome. The nucleotide substitutions result in a change in codon usage bias within codons of one or more protein encoding sequences and no change in amino acid sequences of the proteins. The live-attenuated viruses display unaltered replication in avian hosts for propagation, but attenuated replication in mammalian hosts, when compared to the replication of the parental virus. The live-attenuated viruses in a form of improved vaccines can be used to elicit protective immune responses.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: October 6, 2020
    Assignee: THE UNIVERSITY OF HONG KONG
    Inventors: Lit Man Poon, Lok Yan Fan
  • Patent number: 10792355
    Abstract: A method for inactivated foot-and-mouth disease virus antigen purification and concentration, which relates to the field of biotechnology which includes the following steps of: (1) adding an adaptor protein with an amino acid sequence as shown in SEQ ID NO: 2 into the inactivated foot-and-mouth disease virus antigen, mixing evenly, and incubating; (2) adding a purified carrier, mixing evenly, and incubating the mixture, the purified carrier being a Lactococcus lactis skeleton; and (3) centrifuging and obtaining a precipitate.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: October 6, 2020
    Assignee: JIANGSU ACADEMY OF AGRICULTURAL SCIENCES
    Inventors: Xuwen Qiao, Qisheng Zheng, Xiaoming Yu, Jin Chen, Pengcheng Li, Yuanpeng Zhang, Liting Hou, Jibo Hou
  • Patent number: 10787682
    Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: September 29, 2020
    Assignee: GenVec, Inc.
    Inventors: Douglas E. Brough, Jason G. D. Gall, Duncan McVey
  • Patent number: 10786563
    Abstract: A thermostable formula comprises the following components in percentage by mass: 1% to 5% raffinose, 5% to 10% maltose, 15% to 30% saccharose, 1% to 5% lactose, 1% to 5% glucose, 0.1% to 1.5% polysorbate 80, 0.1% to 0.5% polyethylene glycol 8000, 0.5% to 3% tyrosine, 3% to 6% silk fibroin, and the balance of water for injection. It further discloses a room-temperature-preserved live classical swine fever vaccine and a preparation method thereof, wherein the live classical swine fever vaccine is obtained by mixing the thermostable formula with a live classical swine fever virus solution and then carrying out gradient vacuum drying. The vaccine prepared according to the present invention has a dried foam appearance and presents a glass-layer like structure under a scanning electron microscope, has a glass transition temperature up to more than 50° C.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: September 29, 2020
    Assignee: JIANGSU ACADEMY OF AGRICULTURAL SCIENCES
    Inventors: Fang Lv, Yu Lu, Jibo Hou, Yanhong Zhao, Bihua Deng, Jinqiu Zhang, Xiaoyan Zhang, Xiaoxin Zuo
  • Patent number: 10787501
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: September 29, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Robert Babb, Alina Baum, Gang Chen, Cindy Gerson, Johanna Hansen, Tammy Huang, Christos Kyratsous, Wen-Yi Lee, Marine Malbec, Andrew Murphy, William Olson, Neil Stahl, George D. Yancopoulos
  • Patent number: 10780158
    Abstract: Disclosed herein is a strategy for the engineering of recombinant vaccines against major human and animal pathogens of the paramyxovirus family. Also disclosed are recombinant virus able to replicate without being pathogenic. Also disclosed is a method of immunizing a subject against infection with a that involves administering to the subject a recombinant vaccine disclosed herein.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: September 22, 2020
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Richard Plemper, Veronika von Messling
  • Patent number: 10765733
    Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus filovirus immunogen including a consensus Marburgvirus filovirus glycoprotein MARV GP immunogen, a consensus Ebolavirus Sudan filovirus glycoprotein SEBOV GP immunogen and a consensus Ebolavirus Zaire glycoprotein ZEBOV GP immunogen are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Immunomodulatory methods and methods of inducing an immune response against filovirus, particularly Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire are disclosed. Method of preventing filovirus infection, particularly infection by Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire and methods of treating individuals infected with filovirus infection, particularly infection by Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire are disclosed. Consensus filovirus proteins are disclosed.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: September 8, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Devon Shedlock
  • Patent number: 10765734
    Abstract: The present specification discloses recombinant nucleic acid constructs encoding an immunogenic multiepitope polypeptide comprising two or more polypeptides, recombinant nucleic acid constructs encoding at least two epitopes from two or more internal proteins of influenza virus, compositions comprising such recombinant nucleic acid constructs and methods of eliciting a T cell immune response against an influenza virus in a vertebrate using such recombinant nucleic acid constructs and compositions.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: September 8, 2020
    Assignee: PepTcell Limited
    Inventors: Gregory A. Stoloff, Wilson Romero Caparros-Wanderley
  • Patent number: 10752885
    Abstract: Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: August 25, 2020
    Assignees: Rutgers, the State University of New Jersey, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen University
    Inventors: Hua Zhu, Yimin Li, Ningshao Xia, Tong Cheng, Xiangzhong Ye
  • Patent number: 10736956
    Abstract: Provided herein are immunization regimens for inducing an immune response (e.g., an antibody response) against influenza virus. In specific aspects, the immunization regimens involve the administration of a chimeric hemagglutinin (HA), a headless HA or another influenza virus stem domain based construct (e.g., the HA stem domain or a fragment thereof) to a subject. In certain aspects, the immunization regimens also involve the administration of an influenza virus neuraminidase immunogen.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: August 11, 2020
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Florian Krammer
  • Patent number: 10729758
    Abstract: The invention provides for mosaic influenza virus HA and NA sequences and uses thereof.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: August 4, 2020
    Assignee: Wisconsin Alumni Research Foundation (WARF)
    Inventors: Jorge E. Osorio, Tony Goldberg, Attapon Kamlangdee, Brock Adam Kingstad-Bakke, Tavis Anderson
  • Patent number: 10729765
    Abstract: The present invention discloses a delivery system for nucleic acid vaccines comprising an emulsion of tocol and esters hereof. Vaccines and new ways of administration of DNA vaccines are disclosed.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: August 4, 2020
    Assignee: Statens Serum Institut
    Inventor: Anders Fomsgaard
  • Patent number: 10709779
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more antigens.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: July 14, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Axel Bouchon, Eric Yi-Chun Huang
  • Patent number: 10703802
    Abstract: The present invention provides a composition comprising at least two influenza A virus-neutralizing binding molecules that bind to an epitope in the stem region of influenza A virus hemagglutinin (HA) protein, the method comprising: i) a first binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H2, H5 and H9; ii) a second binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H3, H5, H7 and H9. The mixed composition of the present invention can effectively neutralize the multiple influenza subtypes of both phylogenetic group 1 and phylogenetic group 2 and can be used in combination with a chemical compound. Thus, the composition of the present invention is very useful for the prevention and treatment of a disease by influenza virus.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: July 7, 2020
    Assignee: CELLTRION, INC.
    Inventors: Seung Suh Hong, Shin Jae Chang, Ki Sung Kwon, Kye Sook Yi, Sung Hwan Kim, Eun Beom Lee, Jae Won Lee, So Jung Lee, Ji Young Shin, Myung Sam Cho
  • Patent number: 10703804
    Abstract: Multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains comprising HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: July 7, 2020
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Boerries Brandenburg, Ronald Vogels, Joost A. Kolkman, Robert Heinz Edward Friesen
  • Patent number: 10702597
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: July 7, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
  • Patent number: 10696736
    Abstract: Provided are a broad-spectrum monoclonal anti-Flu B antibody, cell strains generating the antibody, and a composition comprising the antibody; also provided are uses of the antibody for diagnosing, preventing and/or treating an infection of the Flu B and/or diseases caused by the infection.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: June 30, 2020
    Assignee: XIAMEN UNIVERSITY
    Inventors: Yixin Chen, Chenguang Shen, Junyu Chen, Guosong Wang, Mengya Zhang, Ningshao Xia
  • Patent number: 10696737
    Abstract: The object of the invention are monoclonal antibodies against hemagglutinin of H5-serotype influenza viruses selected from the group comprising G-1-31-22, G-2-14-10, G-5-32-5, G-6-42-42, G-7-24-17 and G-7-27-18, having a broad application in immunoprophylaxis and immunotherapy of infections evoked by H5-serotype influenza viruses in humans and animals. The invention also provides hybridomas producing said antibodies, as well as compositions and diagnostic kits containing said antibodies for the detection and typing of H5-serotype influenza viruses and antibodies against H5-serotype influenza viruses in biological samples.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: June 30, 2020
    Assignees: SIEC BADAWCZA LUKASIEWICZ—INSTYTUT BIOTECHNOLOGII I ANTYBIOTYKOW, UNIWERSYTET GDANSKI
    Inventors: Violetta Sączyńska, Violetta Cecuda-Adamczewska, Anna Porębska, Katarzyna Florys, Anna Bierczyńska-Krzysik, Piotr Baran, Agnieszka Romanik-Chruścielewska, Grażyna Płucienniczak, Andrzej Płucienniczak, Piotr Borowicz, Krzysztof Kucharczyk, Boguslaw Szewczyk
  • Patent number: 10696952
    Abstract: Provided herein are methods for the purification of recombinant adeno-associated virus (rAAV) vectors that can be used for gene transfer and specifically for gene therapy or vaccination. Recombinant AAV vectors of the invention are substantially free of in-process impurities, including production components such as cellular nucleic acids, cellular proteins, helper virus, and media components.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: June 30, 2020
    Assignee: Genzyme Corporation
    Inventors: Paulene Mclean Quigley Sheldon, Peter S. Gagnon, Gina Nichols, Barbara A. Thorne